MiMedx launches EPIXPRESS®, a new placental allograft for treating hard-to-heal wounds, enhancing fluid movement in tissue.
Quiver AI Summary
MiMedx Group, Inc. has launched EPIXPRESS®, a new addition to its advanced wound care solutions portfolio. CEO Joseph H. Capper announced that EPIXPRESS builds on the features of the previously successful EPIEFFECT product by incorporating fenestrations for better fluid movement. This lyophilized, tri-layered placental allograft is designed to assist clinicians in treating difficult wounds, such as diabetic foot ulcers and venous leg ulcers, while also being suitable for deep or tunneling wounds. EPIXPRESS provides a biocompatible environment with over 300 regulatory proteins. It is also listed on the Medicare Part B Average Sales Price File, reinforcing MiMedx's commitment to innovation in the healing solutions sector.
Potential Positives
- MiMedx launched EPIXPRESS®, a new addition to its product portfolio, enhancing its offering of AWC solutions for wound care.
- EPIXPRESS features innovative fenestrations, improving fluid movement through the tissue and addressing the needs of clinicians treating hard-to-heal wounds.
- The product is designed for a wide range of applications, including diabetic foot ulcers and venous leg ulcers, positioning the company to better serve various patient needs.
- EPIXPRESS is included in the Medicare Part B Average Sales Price File, making it more accessible for reimbursement, thus potentially increasing market adoption.
Potential Negatives
- None
FAQ
What is EPIXPRESS?
EPIXPRESS is MIMEDX's newest lyophilized human placental-based allograft designed for treating acute and chronic wounds.
How does EPIXPRESS differ from EPIEFFECT?
EPIXPRESS incorporates fenestrations for fluid movement, enhancing the features that clinicians appreciate in EPIEFFECT.
What types of wounds can EPIXPRESS treat?
EPIXPRESS is effective for various wounds, including diabetic foot ulcers, venous leg ulcers, and deep or tunneling wounds.
Is EPIXPRESS covered by Medicare?
Yes, EPIXPRESS is listed on the Medicare Part B Average Sales Price File, indicating coverage eligibility.
Who is MIMEDX?
MIMEDX is a leader in wound care products, dedicated to innovative healing solutions for chronic and hard-to-heal wounds.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MDXG Insider Trading Activity
$MDXG insiders have traded $MDXG stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $MDXG stock by insiders over the last 6 months:
- JOSEPH H CAPPER (Chief Executive Officer) purchased 200,000 shares for an estimated $1,268,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MDXG Hedge Fund Activity
We have seen 100 institutional investors add shares of $MDXG stock to their portfolio, and 87 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FIRST LIGHT ASSET MANAGEMENT, LLC removed 1,525,580 shares (-44.2%) from their portfolio in Q2 2025, for an estimated $9,321,293
- BLACKROCK, INC. added 1,346,741 shares (+13.2%) to their portfolio in Q2 2025, for an estimated $8,228,587
- TRIGRAN INVESTMENTS, INC. added 790,901 shares (+10.4%) to their portfolio in Q2 2025, for an estimated $4,832,405
- ROYCE & ASSOCIATES LP removed 577,703 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $3,529,765
- AMERIPRISE FINANCIAL INC added 548,767 shares (+5332.5%) to their portfolio in Q2 2025, for an estimated $3,352,966
- MILLENNIUM MANAGEMENT LLC added 442,379 shares (+35.9%) to their portfolio in Q2 2025, for an estimated $2,702,935
- NORGES BANK removed 417,900 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $2,553,369
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MDXG Analyst Ratings
Wall Street analysts have issued reports on $MDXG in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Cantor Fitzgerald issued a "Overweight" rating on 07/31/2025
To track analyst ratings and price targets for $MDXG, check out Quiver Quantitative's $MDXG forecast page.
Full Release
MARIETTA, Ga., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the launch of EPIXPRESS®, the Company’s newest addition to its portfolio of AWC solutions.
“I am pleased to announce our latest, organically developed addition to our product portfolio today with the launch of EPIXPRESS,” said Joseph H. Capper, MIMEDX Chief Executive Officer. “With EPIXPRESS, our R&D team has built upon the fantastic attributes the market loves about EPIEFFECT by incorporating fenestrations to allow for fluid movement through the tissue. A hallmark of our success has been, and will continue to be, a commitment to market-driven innovation.”
EPIXPRESS expands MIMEDX’s PURION®-processed placental allograft offering aimed at helping clinicians treat acute and chronic, hard-to-heal wounds. Like EPIEFFECT, EPIXPRESS is a lyophilized product, and features a thick, tri-layer configuration. Additionally, EPIXPRESS adds fenestrations to the sheet configurations to help with fluid movement. EPIXPRESS can be used on a wide range of common conditions, such as diabetic foot ulcers (“DFUs”) and venous leg ulcers (“VLUs”), and other wound types, including those where the need exists to secure the graft in place with sutures. In addition, its product attributes and handling characteristics make it a preferable treatment option for deep or tunneling wounds.
About EPIXPRESS
EPIXPRESS is a lyophilized human placental-based allograft that includes the amnion layer, intermediate layer, and chorion layer. EPIXPRESS is intended for use as a barrier to provide a protective environment in acute and chronic wounds. The product provides a biocompatible human Extracellular Matrix (ECM) and contains 300+ regulatory proteins. Additionally, like MIMEDX’s other Wound products, including EPIFIX®, EPICORD®, EPIEFFECT®, CELERA™ and EMERGE™, EPIXPRESS is listed on the Medicare Part B Average Sales Price File. To learn more, please visit
https://www.mimedx.com/EPIXPRESS/
.
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit
www.mimedx.com
.
Contact:
Matt Notarianni
Investor Relations
470-304-7291
[email protected]
